title: Effects of surfaces and leachables on the stability of biopharmaceuticals.
abstract: Therapeutic proteins are exposed to various potential contact surfaces, particles, and leachables during manufacturing, shipping, storage, and delivery. In this review, we present published examples of interfacial- or leachable-induced aggregation or particle formation, and discuss the mitigation strategies that were successfully utilized. Adsorption to interfaces or interactions with leachables and/or particles in some cases has been reported to cause protein aggregation or particle formation. Identification of the cause(s) of particle formation involving minute amounts of protein over extended periods of time can be challenging. Various formulation strategies such as addition of a nonionic surfactant (e.g., polysorbate) have been demonstrated to effectively mitigate adsorption-induced protein aggregation. However, not all stability problems associated with interfaces or leachables are best resolved by formulation optimization. Detectable leachables do not necessarily have any adverse impact on the protein but control of the leachable source is preferred when there is a concern. In other cases, preventing protein aggregation and particle formation may require manufacturing process and/or equipment changes, use of compatible materials at contact interfaces, and so on. This review summarizes approaches that have been used to minimize protein aggregation and particle formation during manufacturing and fill-finish operations, product storage and transportation, and delivery of protein therapeutics.
authors.affiliation: Formulation Sciences Department, MedImmune, Gaithersburg, Maryland 20878. BeeJ@medimmune.com, jaredsbee@gmail.com.
authors.forename: Jared S
authors.initials: JS
authors.lastname: Bee
authors.forename: Theodore W
authors.initials: TW
authors.lastname: Randolph
authors.forename: John F
authors.initials: JF
authors.lastname: Carpenter
authors.forename: Steven M
authors.initials: SM
authors.lastname: Bishop
authors.forename: Mariana N
authors.initials: MN
authors.lastname: Dimitrova
mesh_terms: D001702:Biopharmaceutics / Q000379:methods*; D002626:Chemistry, Pharmaceutical; D004340:Drug Contamination; D016503:Drug Delivery Systems / Q000295:instrumentation*; D004349:Drug Packaging; D004355:Drug Stability; D004867:Equipment Design; D066329:Protein Aggregates; D055550:Protein Stability; D011506:Proteins / Q000737:chemistry*; D013499:Surface Properties; D013501:Surface-Active Agents / Q000737:chemistry; D013678:Technology, Pharmaceutical / Q000379:methods; D014867:Water / Q000737:chemistry
chemical_list: D066329:Protein Aggregates; D011506:Proteins; D013501:Surface-Active Agents; D014867:Water